Anika Therapeutics (ANIK) Assets Average (2011 - 2026)

Anika Therapeutics (ANIK) has 16 years of Assets Average data on file, last reported at $184.8 million in Q1 2026.

• On a quarterly basis, Assets Average fell 6.02% year-over-year to $184.8 million in Q1 2026; TTM through Mar 2026 was $184.8 million, a 6.02% decrease from a year earlier, with the FY2025 full-year figure at $196.5 million, down 16.98% from the prior year.
• Assets Average for Q1 2026 stood at $184.8 million, down from $189.9 million in the prior quarter.
• Over the last five years, Assets Average for ANIK reached as high as $350.9 million in Q3 2022 and fell as low as $184.8 million in Q1 2026.
• Historically, Assets Average has averaged $273.1 million across 5 years, with a median of $267.2 million in 2024.
• Across the five-year window, Assets Average fell 0.23% in 2023 and declined 28.14% in 2025, its largest moves.
• Year by year, Assets Average stood at $348.4 million in 2022, then dropped by 14.07% to $299.4 million in 2023, then fell by 27.5% to $217.1 million in 2024, then fell by 12.54% to $189.9 million in 2025, then declined by 2.65% to $184.8 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $184.8 million in Q1 2026, $189.9 million in Q4 2025, and $188.6 million in Q3 2025.